Cartalax

Overview

Cartalax is a short synthetic peptide with the sequence Ala-Glu-Asp (commonly abbreviated AED). It belongs to the family of peptide bioregulators associated with the work of Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, a group of low-molecular-weight peptides each studied for effects on a specific tissue.

Cartalax is the member of that family most often discussed in the context of cartilage and connective tissue. The AED sequence is described as corresponding to segments found in structural collagen, and it is studied for a possible role in supporting chondrocyte activity and musculoskeletal tissue.

Most of the evidence to date comes from cell-culture and animal studies, much of it from Russian laboratories. Human clinical data is limited, and Cartalax is not approved by any major regulator for therapeutic use.

How it works

Like other Khavinson short peptides, Cartalax is theorized to act inside the cell rather than through surface receptors. Because of its very small size, it is proposed to enter the cell and nucleus and interact directly with DNA and chromatin, where it may influence the expression of tissue-specific genes. This is described in the literature as an epigenetic-style mechanism rather than classical receptor signaling.

In cartilage explant and cell-culture models, the AED peptide has been reported to increase markers of chondrocyte proliferation and to modulate genes linked to cellular aging. These mechanisms are based on preclinical work and are not established in humans.

Reported benefits

• Support for chondrocyte proliferation and cartilage tissue (cell-culture and animal data)
• Modulation of gene-expression markers associated with connective-tissue aging (preclinical)
• Studied as a possible tissue-specific bioregulator for joint and musculoskeletal health

These are reported or studied effects from early research, not guaranteed outcomes.

Considerations & side effects

Because controlled human trials are lacking, the long-term safety profile of Cartalax is not well characterized. Available reports describe generally good tolerability in preclinical settings, with rare individual hypersensitivity reactions noted, but this cannot be assumed to translate directly to human use.

Product purity varies widely in the research-chemical market, and much of the supporting evidence has not been independently replicated by the broader international research community. Cartalax is not a substitute for evaluation and treatment by a qualified clinician.